NCT02466750Unknown2 期
Phase 2 Open-Label Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92, in Healthy Adult Subjects at Risk of Exposure to Western Equine Encephalitis Virus
U.S. Army Medical Research and Development Command2 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2015年12月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 500
- 试验地点
- 2
- 主要终点
- Number of adverse events
研究概览
简要总结
This study is being conducted to collect safety and immunogenicity data for the WEE vaccine, TSI-GSD 210. Enrollment in this protocol is offered for personnel who enter areas where this virus is used in research or is endemic (an area where this disease process is found to occur frequently).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be 18 to 65 years old at time of consent.
- •Have WEE plaque reduction neutralization 80% titers (PRNT80) < 1:10 for primary series.
- •Have WEE PRNT80 < 1:40 for booster series.
- •If female of childbearing potential, must agree to have a urine pregnancy test on the same day before each vaccine. (Exception: documented hysterectomy or ≥ 3 years of menopause.) The results must be negative. Females must agree to not become pregnant for 3 months after receipt of the last study treatment (vaccination).
- •Be considered at risk for exposure to WEE virus and who have submitted a Request for IND Vaccines for the WEE vaccine.
- •Sign and date the approved informed consent document and HIPAA Authorization.
- •Have in their charts
- •medical history (including concomitant medications) within 60 days of planned first administration of vaccine
- •physical examination and laboratory tests within 1 year
- •previous chest radiograph and electrocardiogram
- •Be medically cleared for participation by an investigator. (Examinations and/or tests may be repeated at the discretion of the enrolling physician.)
- •Be willing to return for all follow-up visits.
- •Agree to report any adverse events (AEs) that may or may not be associated with administration of the vaccine for at least 28 days after administration and agree to report all serious adverse events (for example, resulting in hospitalization) for the duration of the subject's participation in the study.
- •Agree to defer blood, bone marrow, and organ donation for 1 year after receipt of the vaccine.
排除标准
- •Have completed previous WEE vaccine study as a nonresponder (PRNT80 < 1:40).
- •Have clinically significant abnormal laboratory results (including evidence of hepatitis C, hepatitis B carrier state) or elevated liver function tests (two times the normal range or at the discretion of the PI).
- •Have a personal history of an immunodeficiency or received treatment with an immunosuppressive medication, such as systemically administered glucocorticoids (eg, prednisone) within 1 month before planned administration of the vaccine or with other immunosuppressive therapies within 6 months of planned administration of the vaccine. Other immunosuppressive therapies include all cancer chemotherapeutic agents, drugs to prevent transplant rejection, interferons, monoclonal antibodies, protein kinase inhibitors, methotrexate, TNF (tumor necrosis factor) inhibitors, and any other drug determined to be immunosuppressive by the PI. Current administration of topical, inhalational, or intranasal glucocorticoids is not excluded.
- •Have a confirmed HIV infection (antibody positivity).
- •Have a positive pregnancy test or be a breastfeeding female.
- •Have any known allergies to components of the vaccine:
- •formaldehyde eggs neomycin sulfate human serum albumin sodium bisulfite
- •Have administration of another vaccine or investigational product within 28 days of WEE vaccination.
- •Have any unresolved AE resulting from a previous immunization.
- •A medical condition that, in the judgment of the PI, would impact subject safety.
结局指标
主要结局
Number of adverse events
时间窗: Up to 5 years
Percentage of subjects who develop titers of ≥ 1:40 as determined by PRNT80
时间窗: Up to 5 years
Immunogenicity data will be collected for all subjects and will be evaluated for all per-protocol subjects. The primary immunogenicity endpoint measurements will be the percentage of per-protocol subjects who develop titers of ≥ 1:40 as determined by PRNT80 after WEE vaccination at each scheduled time point for which blood samples are drawn and over the entire study period to study completion.
次要结局
- Geometric mean of PRNT80 titers(Up to 5 years)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
2 期
Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in AdultsVenezuelan Equine EncephalomyelitisNCT03531242U.S. Army Medical Research and Development Command500
Unknown
2 期
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy AdultsVenezuelan Equine Encephalomyelitis Virus DiseaseNCT03051386U.S. Army Medical Research and Development Command500
已完成
2 期
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsInfluenzaNCT05606965ModernaTX, Inc.172
撤回
2 期
FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4)TularemiaNCT03867162U.S. Army Medical Research and Development Command
Unknown
2 期
A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaNCT00925314Cosmo Bioscience20